Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
Issue: Sep/Oct 2012 - Volume 16, Number 5
View All Articles in Issue
Page(s): 428-430
Download in electronic PDF format for $75
Abstract: Transdermal acetaminophen in Pluronic lecithin organogel (APAP-PLO) has been anecdotally reported as beneficial when used in cancer patients in the hospice setting. However, there is currently no published information regarding the stability of APAP-PLO. The objective of this study was to identify an appropriate formulation of APAP-PLO and to evaluate the stability of that formulation in order to determine an appropriate beyond-use date. APAP-PLO 50% was prepared by a local compounding pharmacy and analyzed at 0, 7, 14, 28, 45, 60, 90, and 180 days using a stability-indicating high-performance liquid chromatographic method. The mean concentrations and standard deviations were determined for each time point. Physical stability was also assessed by visual observation at each time point. The beyond-use date was determined as the time period that the samples maintained at least 90 percent of the initial concentration. At 180 days, the APAP-PLO was physically stable as noted by visual observation, and the concentration was 102 ± 4.8 percent of initial concentration indicating that a beyond-use date of 180 days would be appropriate for this formulation.
Related Keywords:
Gina F. Peacock, PhD, Jurgita Sauvageot, PharmD, acetaminophen, transdermal administraiton, antipyretic, fever, analgesic, analgesia, stability, formulation
Related Categories:
EXCIPIENTS, FORMULATIONS, PAIN MANAGEMENT, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date
Peacock Gina F, Sauvageot Jurgita
|
Sep/Oct 2012
Pg. 428-430
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita, Addo Richard T
|
Jul/Aug 2014
Pg. 348-350
|
Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita
|
Jul/Aug 2014
Pg. 345-347
|
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita
|
May/Jun 2014
Pg. 253-255
|
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date
Peacock Gina F, Sauvageot Jurgita, Hill Ashley, Killian Alyssa
|
Jan/Feb 2016
Pg. 81-85
|
Acetaminophen 50% Pluronic Lecithin Organogel Gel
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 146
|
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
|
May/Jun 2014
Pg. 256-261
|
Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
|
Jan/Feb 2021
Pg. 73-81
|
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
|
May/Jun 2013
Pg. 247-253
|
Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Pignato Alyssa, Pankaskie Marvin, Birnie Christine
|
Nov/Dec 2010
Pg. 522-525
|
The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L, Williams LaVonn A
|
Jan/Feb 2012
Pg. 62-63
|
Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model
Baneshi Marzieh, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X
|
Sep/Oct 2023
Pg. 424-430
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Assignment of a Beyond-Use Date for Compounded Preparations
Allen Loyd V Jr
|
Nov/Dec 2000
Pg. 474-475
|
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
|
May/Jun 2005
Pg. 242-246
|
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
|
Mar/Apr 2004
Pg. 101-105
|
Beyond-use Date: Establishment and Maintenance
Osteen Richard
|
Nov/Dec 2012
Pg. 471-474
|
Acetaminophen 10-mg/mL Rectal Solution
Allen Loyd V Jr
|
Sep/Oct 2008
Pg. 447
|
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
|
Mar/Apr 2017
Pg. 164-170
|
Return to Top |